Amorphous solid dispersions: Utilization and challenges in preclinical drug development within AstraZeneca

AB Anane-Adjei, E Jacobs, SC Nash, S Askin… - International Journal of …, 2022 - Elsevier
The poor aqueous solubility of many active pharmaceutical ingredients (APIs) dominates
much of the early drug development portfolio and poses a major challenge in …
被引用次数：39 相关文章

[引用][C] Amorphous solid dispersions: Utilization and challenges in preclinical drug development within AstraZeneca

AB Anane-Adjei, E Jacobs, SC Nash, S Askin… - International Journal of …, 2022 - cir.nii.ac.jp
Amorphous solid dispersions: Utilization and challenges in preclinical drug development within
AstraZeneca | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …

Amorphous solid dispersions: Utilization and challenges in preclinical drug development within AstraZeneca.

AB Anane-Adjei, E Jacobs, SC Nash… - International Journal …, 2021 - europepmc.org
The poor aqueous solubility of many active pharmaceutical ingredients (APIs) dominates
much of the early drug development portfolio and poses a major challenge in …

Amorphous solid dispersions: Utilization and challenges in preclinical drug development within AstraZeneca

AB Anane-Adjei, E Jacobs, SC Nash… - International …, 2022 - pubmed.ncbi.nlm.nih.gov
The poor aqueous solubility of many active pharmaceutical ingredients (APIs) dominates
much of the early drug development portfolio and poses a major challenge in …